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Background: Acute partial transverse myelitis (APTM)
may be the first clinical symptom of multiple sclerosis
(MS) or may remain a monophasic event.
Objectives: To evaluate the risk of conversion to MS
and long-term disability, and to determine prognosis fac-
tors for disability.
Design: We identified patients with no previous his-
tory of neurological disease who experienced APTM be-
tween January 1998 and December 2005 and were fol-
lowed up at 3 university hospitals in France. Data on the
patients’ demographics and clinical states during follow-
up, as well as data on cerebrospinal fluid (CSF) analy-
sis, brain and spinal cord magnetic resonance imaging
(MRI), and visual evoked potentials, were analyzed.
Setting: Neurology departments of 3 university hospi-
tals in Lille, Strasbourg, and Rouen, France, respec-
tively.
Patients: A total of 85 patients with no previous his-
tory of neurological disease who experienced APTM.
Results: The mean (SD) follow-up period was 104.8
(29.8) months. There were 57 women (67%) and 28 men
(33%), with a mean (SD) age at onset of 36.7 (11.7) years.
At the end of follow-up, 53 patients (62%) were classi-
fied as having MS with a mean (SD) Expanded Disabil-
ity Status Scale score of 2.6 (1.8), 1 patient (1%) was clas-
sified as having postinfectious myelitis, 1 (1%) as having
neuromyelitis optica, 1 (1%) as having Sjo¨gren syn-
drome, and 29 (34%) still had APTM of undetermined
etiology. Oligoclonal bands in CSF were more frequent
in patients with MS (92%) than in patients with APTM
of undetermined etiology (38%). Brain MRI results were
abnormal in 87% of patients with MS and 27% of pa-
tients with APTM of undetermined etiology; visual evoked
potentials were abnormal in 43% of patients with MS and
4% of patients with APTM of undetermined etiology. Oli-
goclonal bands in CSF (odds ratio, 15.76 [95% CI, 2.95-
84.24]) and at least 1 MRI-detected brain lesion (odds
ratio, 7.74 [95% CI, 2.42-24.74]) were independent pre-
dictive factors for conversion to MS.
Conclusion: Our study confirms that abnormal brain MRI
results and the presence of oligoclonal bands in CSF are
2 independent predictive factors for conversion to MS.
No clinical, biological, or MRI factor at onset was pre-
dictive of long-term disability.
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M ULTIPLE SCLEROSIS(MS) is the most com-mon inflammatory dis-ease of the central ner-vous system affecting
young adults in Western countries. It is
characterized by a huge interindividual
variability of clinical symptoms and an un-
predictable course ranging from asymp-
tomatic sequelae to severe disability. Early
initiation of treatment has proved effec-
tive in delaying the second neurological
episode and reducing long-term disabil-
ity.1 It is therefore mandatory to identify
as early as possible patients who may de-
velop the disease. First attacks of MS, also
called clinically isolated syndrome (CIS),
usually consist of optic neuritis, brain-
stem involvement, or partial myelitis. Con-
version rates of CIS to MS have previ-
ously been studied in 3 populations of
patients presenting with CIS: a patient
population in London, England, over pe-
riods of 7, 14 and 20 years2,3; in Barce-
lona, Spain, over 7 years4; and in North
America, electively concerning optic neu-
ritis, over 15 years.5 In these 3 studies, the
probability of developing MS ranged from
42% to 63%, but the authors of these stud-
ies did not analyze each initial symptom,
especially acute partial transverse myeli-
tis (APTM). This specific manifestation
was only referred to in small and retro-
spective studies: the conversion rate to MS
was evaluated at between 11% and
57.7%.6-10 Some predictive factors for
conversion from CIS to MS have been iden-
tified: sensory symptoms,7 presence of oli-
goclonal bands (OCBs) in the cerebrospi-
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lesions detected on magnetic resonance imaging (MRI)
scans.7,10
The aim of our study was to evaluate the long-term
risk for conversion from APTM to MS. The second ob-
jective was to determine prognosis factors for disability.
METHODS
PATIENTS
We included 87 patients referred to the neurology depart-
ments of 3 university hospitals (in Lille, Strasbourg, and Rouen,
France, respectively) for myelitis between January 1998 and
October 2005. Data were collected prospectively in Lille (43
patients) and retrospectively in Strasbourg and Rouen (44 pa-
tients), and patients were followed up until May 2010. For the
latter patients, we performed a review of the medical records
of those who received a diagnosis of myelitis, encephalomy-
elitis, and MS in the hospital databases. We used the inclusion
criteria for APTM proposed by Ford et al11: acute or subacute
motor or sensory symptoms with or without sphincter dys-
function, occurrence of symptoms lasting a minimum of 48
hours and a maximum of 3 weeks, neither clinical nor radio-
logical evidence of spinal compression, and no previous his-
tory of neurological symptoms. The exclusion criterion was a
diagnosis of transverse myelitis (patients with a severe senso-
rimotor feature and an extended hypersignal on a spinal cord
MRI scan). An exhaustive laboratory investigation was also per-
formed to exclude medullary infarct, infectious myelitis, or vas-
culitis, as detailed in a previous study.12
Demographic data (age and sex of patients) and clinical fea-
tures (motor or sensory deficits, sphincter dysfunction, and acute
or subacute onset) were noted on admission. Initial symp-
toms were classified as acute if they developed in less than 3
days. At the end of follow-up, patients were classified into 3
groups: the “MS group,” comprising patients who fulfilled the
revised criteria of McDonald et al13; the “undetermined group,”
comprising patients who did not experience any new neuro-
logical symptoms; and the “other diseases group,” comprising
patients with Sjo¨gren syndrome, postinfectious myelitis, or neu-
romyelitis optica. For patients in the MS group, disability sta-
tus at end point was defined as the 6-month sustained Ex-
panded Disability Status Scale score.14
On admission, patients underwent 1.5-T MRI of the spinal
cord. T1, T2, and gadolinium-enhanced sequences of the cer-
vical, thoracic, and lumbar spine were performed in the sagit-
tal plane. If a lesion was detected, complementary sequences
in the axial plane were acquired. We evaluated the number of
lesions, their localization in the sagittal and axial planes (an-
terior, central, posterior, and lateral), and their extent (num-
ber of vertebral levels).
Patients also underwent 1.5-T MRI of the brain, with T1,
T2, and T1 gadolinium infusion sequences. We used the cri-
teria of Barkhof et al15 to evaluate these brain MRI scans, and
we applied the revised criteria of McDonald et al13 for a diag-
nosis of MS. Patients also underwent evaluation of visual evoked
potentials (VEPs).
A lumbar puncture was performed for all patients. Analy-
sis of the CSF included evaluation of cell count, cytology, pro-
tein content, and intrathecal IgG synthesis. For 72 patients, OCBs
were searched for by using the isoelectrofocusing method.
The patients were followed up with a clinical evaluation at
3, 6, and 9 months after the occurrence of APTM and every year
during the remainder of our study. Patients also consulted with
us when a relapse occurred. A relapse was defined as an exac-
erbation of preexisting symptoms or the occurrence of new
symptoms sustained for at least 48 hours. At the end of our study,
we noted the Expanded Disability Status Scale score assessed
by the patient’s neurologist. During the follow-up period, 71
of 85 patients (84%) had a second spinal cord MRI scan after a
mean (SD) of 13.7 (16.4) months, and 75 of 85 patients (88%)
had a second brain MRI scan.
Statistical analysis was based on the 2 test, and we also per-
formed a binary logistic regression based on Spearman coeffi-
cients. P .05 was assumed to be statistically significant. Re-
sults are presented as mean (SD) values. We used Matlab16
software (MathWorks) for Windows (Microsoft).
RESULTS
PATIENTS
Six of the 87 patients initially identified as having APTM
were lost to follow-up: 2 during the first year and 4 after
a mean of 76.7 months, all of whom had been included
prospectively. The first 2 patients received a diagnosis
of MS, as did 2 of the other 4 patients. We estimated the
follow-up period to be long enough for the latter 4 pa-
tients to be included in the statistical analysis.
Of the 85 remaining patients, 53 (62%) had APTM that
converted to MS, 29 (34%) still had APTM of undeter-
mined etiology, 1 (1%) had postinfectious myelitis, 1 (1%)
had Sjo¨gren syndrome, and 1 (1%) had neuromyelitis op-
tica. The mean (SD) follow-up period was 104.8 (29.8)
months (range, 43.8-172.5 months).
Some differences were found between prospectively
included patients (in Lille) and retrospectively included
patients (in Rouen and Strasbourg). The ratio of pa-
tients with MS to patients without was higher in
patients from Lille (31 of 40 patients [77%] vs 22 of 42
patients [52%]; P=.03). Seven of the 31 patients with MS
from Lille (23%) had sphincter dysfunction compared
with none of the 22 patients with MS from Rouen and
Strasbourg (P=.048). The MRI-detected lesions were more
frequently located in the dorsal (61% vs 29%; P=.04) or
dorsolateral part (100% vs 78%; P=.049) of the spinal
cord in patients with MS from Lille.
CLINICAL FINDINGS
The clinical features of the MS group and the undeter-
mined groups are presented in Table1. There was no sta-
tistical difference in terms of age, sex ratio, or presenting
signs. Most of the patients had sensory signs (96% in the
MS group and 100% in the undetermined group). Acute
partial transverse myelitis was preferentially acute for pa-
tients in the undetermined group (35% of patients in the
undetermined group vs 15% of patients in the MS group;
P=.03) and was subacute for patients whose APTM sub-
sequently converted to MS (85% of patients in the MS group
vs 66% of patients in the undetermined group; P=.03).
MRI FINDINGS
Spinal cord MRI results are summarized in Table 2. Of
the 85 analyzed patients, 65 (76%) had an axial plane MRI
analysis, and 75 (88%) a gadolinium injection. We noted
a mean (SD) of 1.23 (0.78) lesions in the MS group and
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1.21 (0.94) lesions in the undetermined group (P=.91),
extending over a mean (SD) of 1.51 (1.16) and 1.33 (1.00)
vertebral levels, respectively (P=.50). The location of le-
sions in the sagittal plane was similar: more than half were
in either the cervical region (52% in the MS group and
48% in the undetermined group) or the dorsal region (48%
in both groups). Lesions were seldom in the anterior part
of the spinal cord (2% in the MS group and 0% in the
undetermined group) but were preferentially in the pos-
terolateral (97%) or lateral (49%) part in the MS group.
Centrally located lesions were more frequent in the un-
determined group than in the MS group (42% vs 18%;
P=.02). Gadolinium enhancement was more frequent in
the MS group (55%) than in the undetermined group (55%
vs 35%; P=.02).
Brain MRI results are shown in Table 3. The fre-
quency of patients with lesions fulfilling 3 or more of the
criteria in Barkhof et al15 was higher in the MS group (54%)
than in the undetermined group (54% vs 0%; P=910−6).
Conversely, brain MRI results were normal in 73% of the
patients in the undetermined group compared with 13%
of the patients in the MS group.
CSF ANALYSIS
The CSF results are presented in Table 3. There were no
statistical differences between the MS group and the un-
determined group in terms of mean (SD) cell counts (13.5
[17.3] vs 9.5 [24.3] cells/mm3, respectively) or mean (SD)
protein levels (4.5 [1.8] vs 5.2 [2.9] g/dL, respectively
[to convert to grams per liter, multiply by 10.0]). How-
ever, OCBs in the CSF were more frequently observed
in patients in the MS group than in patients in the un-
determined group (92% vs 38%; P=410−6).
VISUAL EVOKED POTENTIALS
The results of VEP studies are presented in Table 3. Of
the 73 patients examined (47 patients from the MS group
and 26 patients from the undetermined group), 20 pa-
tients from the MS group (43%) and 1 patient from the
undetermined group (4%) had abnormal results
(P=510−7).
RISK OF CONVERSION TO MS
Using the 2 test for single variable analysis, we found 6
factors predictive of conversion to MS: subacute onset
of APTM (P=.03), presence of lateral (P=.03) and pos-
terolateral (P=.011) spinal cord lesions, gadolinium en-
hancement of these lesions (P=.02), MRI-detected brain
abnormalities fulfilling 3 or 4 of the criteria in Barkhof
et al15 (P=910−6), OCBs in the CSF (P=410−6), and
abnormal VEPs (P=510−7).
Using binary logistic regression, we identified 2 vari-
ables as risk factors: brain abnormalities, with an odds ra-
tio (OR) of 7.74 (95% CI, 2.42-24.74), and OCBs, with an
OR of 15.76 (95% CI, 2.95-84.24). According to these 2
variables, it is possible to classify patients as shown in our
Figure. We can also estimate the sensitivity (91.3%), the
specificity (62.5%), the positive predictive value (82.4%),
and the negative predictive value (78.9%) of OCBs.
















MS (n = 53) 34.8 (17-54) 14 39 21 (40) 51 (96) 7 (13) 8 (15)a 45 (85)a
Undetermined
(n = 29)
38.6 (16-76) 13 16 10 (34) 29 (100) 3 (10) 10 (34) 19 (66)
Combined (n = 82) 36.7 (16-76) 27 55 31 (38) 80 (98) 20 (24) 18 (22) 64 (78)
Abbreviation: MS, multiple sclerosis.
aP = .03 (comparison between the MS and undetermined groups determined by use of the 2 test).










Patients,a No./Total No. (%)
Sagittal Plane Axial Plane
Gadolinium





MS (n = 53) 1.23 (0-6) 1.51 27/52 (52) 25/52 (48) 5/52 (10) 1/39 (3) 19/39 (49)b 19/39 (49) 7/39 (18)c 38/39 (97)d 26/39 (67) 26/47 (55)c
Undetermined
(n = 29)
1.21 (0-5) 1.33 14/29 (48) 14/29 (48) 2/29 (7) 0/26 (0) 5/26 (19) 14/26 (54) 11/26 (42) 19/26 (73) 16/26 (62) 9/26 (35)
Combined
(n = 82)
1.22 (0-6) 1.42 41/81 (51) 39/81 (48) 7/81 (9) 1/65 (2) 24/65 (37) 33/65 (51) 18/65 (28) 57/65 (88) 42/65 (65) 35/73 (48)
Abbreviation: MS, multiple sclerosis.
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PREDICTIVE FACTORS
OF LONG-TERM DISABILITY
None of the clinical variables (type of symptom and type
of onset), biological variables (cell count, protein level,
and presence of OCBs), or radiological variables (brain
and spinal cord MRI results and VEPs) were predictive
of disability at the end of follow-up in the MS group.
COMMENT
To our knowledge, this study is one of the largest stud-
ies of APTM (85 patients) and, after a long follow-up pe-
riod (8.7 years), confirms that there are 2 risk factors for
conversion to MS: white matter lesions on initial brain
MRI scan and the presence of OCBs in CSF. These 2 risk
factors are associated with ORs of 7.7 (95% CI 2.42-
24.74) and 15.8 (95% CI, 2.95-84.24), respectively, for
conversion to MS. None of the studied clinical, biologi-
cal, or radiological variables was predictive of long-term
disability in patients with MS.
Studies on APTM as a CIS are relatively rare. Only 2
of the 8 published studies7-11 were prospective: one11 with
15 patients followed up for 38 months and the other7 with
52 patients followed up for 35 months. In our study, we
included 85 patients (data collected prospectively for 41
patients [48%] and retrospectively for 44 patients [52%])
who were followed up for a mean period of 104.8 months,
constituting, to our knowledge, the longest reported fol-
low-up period. This collaborative work between 3 medi-
cal centers allowed us to smooth confounding factors and
geographical specificities, but it may also have intro-
duced a bias due to differences in complementary ex-
aminations. Despite our efforts to standardize patient in-
clusion criteria, there may well have been discrepancies
in the collection of data on patients, as demonstrated by
Table 3. Results of Paraclinical Examination at Presentation
Group
Patients, No./Total No.


















MS 7/52 (13)a 45/52 (87)b 28/52 (54)c 4.5 (1.6-9.2) 13.5 (0-87) 43/47 (91)d 20/46 (43)e
Undetermined 19/26 (73) 7/26 (27) 0/26 (0) 5.2 (1.9-14.3) 9.38 (0-133) 10/26 (38) 1/26 (4)
Combined 26/78 (33) 52/78 (67) 28/78 (36) 4.8 (1.6-14.3) 11.42 (0-133) 53/73 (73) 21/72 (29)
Abbreviations: CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; MS, multiple sclerosis; OCBs, oligoclonal bands; VEPs, visual evoked potentials.
SI conversion factor: To convert protein to grams per liter, multiply by 10.0.
aP = 5  10−7.
bP = 5.43  10−7.
cP = 9  10−6.
dP = 4  10−6.
eP = .001.
87 Patients With APTM
2 Lost to follow-up
12 Had incomplete data
47 (64%) With at least 1 MRI-detected brain lesion
26 (36%) With no MRI-detected brain lesions
36 (92%) With MS
3 (8%) With other disease
3 (37%) With MS
5 (63%) With other disease
6 (46%) With MS
7 (54%) With other disease
1 (8%) With MS
12 (92%) With other disease
39 (83%) Had OCBs in CSF
8 (17%) Had no OCBs in CSF
13 (50%) Had OCBs in CSF
13 (50%) Had no OCBs in CSF
73 With CIS
Figure. Flow diagram of patients with acute partial transverse myelitis (APTM), according to the results of brain magnetic resonance imaging (MRI) and
cerebrospinal fluid (CSF) analysis. CIS indicates clinically isolated syndrome; MS, multiple sclerosis; and OCBs, oligoclonal bands.
ARCH NEUROL / VOL 69 (NO. 3), MAR 2012 WWW.ARCHNEUROL.COM
360
©2012 American Medical Association. All rights reserved.
Corrected on March 28, 2012Downloaded From:  by a Université de Strasbourg User  on 04/16/2018
the greater proportion of patients with MS in Lille (77%,
included prospectively) than in Rouen or Strasbourg (52%,
included retrospectively). This proportion of conver-
sion to MS in prospectively included patients is greater
than in retrospective studies,6,8-10 illustrating the impor-
tance of standardizing the recruitment method.
Of the 85 patients who experienced APTM, 53 (62%)
had APTM that converted to MS, and 29 (34%) did not
develop any further disease. This conversion rate is simi-
lar to the rate previously described in the prospective study
by Cordonnier et al7 (57.7%) but is higher than the rates
described in Sellner et al10 (42.5%) and Scott et al9 (43.3%).
This difference may be due to the shorter mean fol-
low-up in these studies (46 and 61 months, respec-
tively) compared with our mean follow-up (104.8
months). Considering that there are all types of CISs (op-
tic neuritis, cerebral, or brainstem involvement), their
combined conversion rate to MS is lower: 49% after 7
years.4 The follow-up duration may be, in part, respon-
sible: this rate increases from 50% after 15 years5 to 63%
after 20 years.3 Because differential diagnoses of APTM
are fewer than in other CISs, the conversion rate may be
increased: APTM seems to be a CIS with a high risk of
conversion to MS.
Univariate analysis of clinical data at onset showed that
subacute onset of symptoms was more frequent in pa-
tients who went on to develop MS than in other patients
(85% vs 66%; P=.03). This factor was not detected by
the binary logistic regression, in part because of its weak-
ness. Only 1 of the 8 studies dealing with the APTM con-
version risk to MS found a predictive clinical variable:
sensory symptoms (P=.009).7
The characteristics of the spinal cord MRI scan at
onset are interesting. Univariate analysis identified that
lateral (P=.03), posterolateral (P=.011), or gadolinium-
enhanced lesions (P=.02) were associated with MS. Con-
versely, centro-medullary lesions were more frequent in
APTM in the undetermined group than in the MS
group (P=.02). Unfortunately, these factors were not
significant in binary logistic regression. This may in
part be due to the fact that only 78% of patients
underwent axial sections, thereby reducing the statisti-
cal power of our results. Cordonnier et al7 also identi-
fied the posterolateral location of spinal cord lesions
as a predictive factor for conversion to MS (P= .01),
but none of the other studies8-11 confirmed this result.
Nevertheless, spinal cord lesions in CIS have never
been independently assessed as a factor for conversion
to MS.
Brain MRI data can discriminate among patients. In
the MS group, 54% of patients had lesions fulfilling the
criteria in Barkhof et al,15 compared with none in the un-
determined group (P=910−7); conversely, patients with
no brain lesions were more frequent in the latter group
(73%, compared with 13% in the MS group; P=510−7).
The presence of brain lesions, also significant in binary
logistic regression (OR, 7.74 [95% CI, 2.42-24.75]), has
already been identified in patients with APTM7,10 and in
patients with CIS3,5,16 as a predictive factor for conver-
sion to MS. We failed to show any correlation between
this and long-term disability, whereas several studies2-4
have reported a correlation. However, these studies2-4 in-
cluded more patients (100-175 patients) and followed
them between 7 and 20 years.3,4
Abnormal VEPs and the presence of OCBs are also pre-
dictive of conversion to MS. Visual evoked potentials were
abnormal in 1 patient (3%) in the undetermined group
compared with 20 patients (36%) in the MS group. How-
ever, the presence of OCBs in CSF was the only factor
identified by binary logistic regression (OR, 15.76 [95%
CI, 2.95-84.24]). This factor was identified by Sellner et
al,10 but the OR was 4.73 (95% CI, 1.09-6.76). The lon-
ger follow-up in our study (104.8 months compared with
45 months in Sellner et al10) may partly explain this dif-
ference. Negative brain MRI results and the absence of
OCBs have a high clinical interest: patients developed MS
only in 8% of cases compared with 46% or 54% of cases
if OCBs were present (Figure). This result highlights the
importance of analyzing CSF when the initial brain MRI
result is normal.
Neither VEPs nor OCBs were predictive of the long-
term disability in our patients. This result is in line with
that of Schneider et al17 but not with those of other stud-
ies.18,19 The data of Mandrioli et al18 must be analyzed with
caution because their study was retrospective and fo-
cused on patients with clinically definite MS rather than
on patients with CIS.
During this long-term (8.7 years) follow-up of 85 pa-
tients with APTM, 53 (62%) had APTM that converted
to MS. Brain MRI scans that detected at least 1 lesion (OR,
7.74 [95% CI, 2.42-24.74]) and the presence of OCBs in
CSF (OR, 15.76 [95% CI, 2.95-84.24]) were 2 indepen-
dent factors highly predictive of conversion to MS. None
of the clinical, biological, or radiological factors were pre-
dictive of long-term disability.
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